AbbVie’s $100bn deal aligns drug pricing with domestic manufacturing goals
AbbVie has entered into a landmark $100 billion agreement that will see the company lower prices on select Medicaid drugs while simultaneously expanding its distribution through the TrumpRx direct-to-patient platform. This strategic move is indicative of a broader trend within the pharmaceutical industry, where companies are increasingly focusing on aligning drug pricing with domestic manufacturing…









